Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 16/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 16/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12145921 | 0.94 | CHRNB2 (0.58) | CHRNB2CHRNA4HTR1AHTR1DHTR1B | |
| SCHEMBL22601459 | 0.86 | MAPT (0.50) | CHRNB2CHRNA4 | |
| SCHEMBL16256660 | 0.84 | MAPT (0.53) | CHRNB2CHRNA4 | |
| SCHEMBL8108975 | 0.82 | CHRNB2 (0.55) | CHRNB2CHRNA4HTR3AHTR6ADRB1 | |
| Hydrochloric Acid SCHEMBL29978671 | 0.81 | CHRNB2 (0.54) | CHRNB2CHRNA4HTR3AHTR6ADRB1 | |
| Hydrochloric Acid SCHEMBL28343784 | 0.81 | CHRNB2 (0.54) | CHRNB2CHRNA4HTR3AHTR6ADRB1 | |
| SCHEMBL231910 | 0.80 | CHRNB2 (0.68) | CHRNB2CHRNA4ADRB1 | |
| SCHEMBL382350 | 0.78 | CHRNB2 (0.58) | CHRNB2CHRNA4HTR1DHTR3AHTR6 | |
| SCHEMBL31774414 | 0.78 | CHRNB2 (0.58) | CHRNB2CHRNA4HTR1DHTR3AHTR6 | |
| SCHEMBL20249102 | 0.77 | CDK4 (0.43) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CHRNB2 4863/4885CHRNA4 4628/4885HTR1A 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.